CD3+ (tumor, P = 0.0491; total, P = 0.0218), CD3+CD4+ (tumor, P = 0.0201; total, P = 0.0305), and CD20+ cells (tumor, P = 0.0425; stroma, P = 0.0214; total, P = 0.0176) and TLS (P = 0.0433) were more abundant in the TIME of MPR patients (Figures 4E–H) over that of the non-MPR patients. The gene discussed is CD4; the disease is neoplasm.